Pfizer Inc. $PFE Shares Sold by Founders Capital Management

Founders Capital Management cut its stake in Pfizer Inc. (NYSE:PFE) by 12.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,705 shares of the biopharmaceutical company’s stock after selling 2,008 shares during the period. Founders Capital Management’s holdings in Pfizer were worth $356,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter worth about $27,000. North Capital Inc. acquired a new position in Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd acquired a new position in Pfizer in the 1st quarter valued at about $28,000. Horizon Financial Services LLC acquired a new position in Pfizer in the 1st quarter valued at about $35,000. Finally, WPG Advisers LLC acquired a new position in Pfizer during the 1st quarter worth approximately $35,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PFE. Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Morgan Stanley upped their target price on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Trading Up 6.8%

PFE stock opened at $25.46 on Wednesday. The company has a market cap of $144.75 billion, a price-to-earnings ratio of 13.54, a PEG ratio of 0.77 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $24.55 and a 200-day simple moving average of $24.11. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.